OncoAssure

Prostate Test

Multigene prognostic signature used to assess the probability of aggressive disease in men recently diagnosed with early-stage prostate cancer.

R

CLIA-Certified Lab Service

R

Research Service

Order Collection Kit

Early Detection

Diagnosis

Therapy Selection

Therapy Monitoring

Introducing OncoAssure Prostate Test

OncoAssure Prostate is a Laboratory developed test (LDT) for assessing the probability of aggressive disease in men recently diagnosed with early-stage prostate cancer. The OncoAssure Prostate test estimates the risk of aggressive disease based on a continuous risk score calculated from a linear combination of normalized expression levels of the OncoAssure Prostate gene panel combined with patient clinical information. Men whose OncoAssure Prostate risk score indicates they have a low risk of underlying aggressive disease may be suitable candidates for active surveillance. Additionally, the OncoAssure Prostate test can be used to estimate a patient’s risk for 5-year biochemical recurrence following the radical prostatectomy (RP) procedure using the gene expression profile of FFPE prostate cancer tissue samples collected at RP.

Order Collection Kit

Identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment

The 6-gene expression assay assesses the risk of aggressive disease post-diagnosis and the risk of biochemical recurrence over a 5-year period post-surgery

Fast turnaround time

Comprehensive test report

Order Collection Kit

X